新辅助化疗FEC方案和TEC方案对乳腺癌患者的疗效  

Efficacy of neoadjuvant chemotherapy with FEC and TEC regimen on breast cancer

作　　者：王蓓[1,2] 傅健飞[1] 洪中武[1] 

机构地区：[1]金华市中心医院肿瘤科,浙江金华321000 [2]浙江省中医院乳腺科

出　　处：《癌症》2009年第3期292-296,共5页Chinese Journal of Cancer

摘　　要：背景与目的:乳腺癌新辅助化疗能使肿瘤缩小,降低临床分期,提高综合治疗疗效。本研究目的在于探讨新辅助化疗FEC方案和TEC方案对乳腺癌患者的疗效。方法:自1998年4月至2006年4月,112例乳腺癌患者接受了新辅助化疗(新辅助化疗组),其中77例采用了FEC方案化疗,35例采用了TEC方案化疗,21d为一周期,共2～3个周期。同期105例直接接受手术治疗的乳腺癌患者作为对照组。两组均接受了术后化疗。结果:随访时间10～107个月,全部患者接受随访,中位随访时间61.4个月。新辅助化疗后临床完全缓解31例(27.7%),总有效率79.5%。新辅助化疗组与直接手术组比较,术后5年无瘤生存率(67.2%vs.49.4%,χ2=4.092,P=0.043)及5年总生存率(84.7%vs.69.1%,χ2=4.034,P=0.045)均有提高。结论:采用FEC方案和TEC方案对可手术的乳腺癌患者进行新辅助化疗可取得较高的缓解率,有助于提高5年无瘤生存率和总生存率。Background and Objective. Neoadjuvant chemotherapy can remarkably decrease tumor size and stage, and improve the efficacy of comprehensive treatment on breast carcinoma. This study was to investigate the efficacy of neoadjuvant chemotherapy with FEC and TEC regimen on breast cancer. Methods; From April 1998 to April 2004, 112 breast cancer patients were treated with neoadjuvant chemotherapy. Among them, 77 were treated with FEC regimen and 35 with TEC regimen for 2-3 cycles before operation. Simultaneously, 105 breast cancer patients who only received postoperative chemotherapy were regarded as control. Results： All patients were followed up for 10-107 months （median, 61.4 months）. After neoadjuvant chemotherapy, 31 patients （27.7%） had clinical complete remission, and the total response rate was 79.5%. The 5-year disease-free and overall survival rates were significantly higher in neoadjuvant chemotherapy group than in control group （67.2% vs. 49.4%, χ^2=4.092, P= 0.043; 84.7% vs. 69.1%, χ^2=4.034, P=0.045）. Conclusion： Neoadjuvant chemotherapy with FEC and TEC regimens is an effective treatment for operable breast cancers, and can prolong the long-term survival and disease-free survival after operation.

关 键 词：乳腺肿瘤 新辅助化疗 疗效 预后 

分 类 号：R737.9[医药卫生—肿瘤]